PLA2G2A+ Cancer-Associated Fibroblasts Mediate Pancreatic Cancer Immune Escape Via Impeding Antitumor Immune Response of CD8+ Cytotoxic T Cells.

Weiyu Ge,Ming Yue,Ruirong Lin,Tianhao Zhou,Haiyan Xu,Yu Wang,Tiebo Mao,Shumin Li,Xiuqi Wu,Xiaofei Zhang,Yongchao Wang,Jingyu Ma,Yanling Wang,Shengbai Xue,Daiyuan Shentu,Jiujie Cui,Liwei Wang
DOI: https://doi.org/10.1016/j.canlet.2023.216095
IF: 9.756
2023-01-01
Cancer Letters
Abstract:Our previous research defined a novel metabolic cancer associated fibroblasts subset (meCAFs) enriched in loose-type pancreatic ductal adenocarcinoma (PDAC) and related to CD8+ T cells accumulation. Consistently, the abundance of meCAFs was associated with poor prognosis but better immunotherapy responses in PDAC patients. However, the metabolic characteristic of meCAFs and its cross-talk with CD8+ T cells remain to be elucidated. In this study, we identified PLA2G2A as a marker of meCAFs. In particular, the abundance of PLA2G2A+ meCAFs was positively related to the accumulation of total CD8+ T cells and negatively correlated with clinical outcomes of PDAC patients and infiltration of intratumoral CD8+ T cells. We demonstrated that PLA2G2A+ meCAFs substantially attenuated the antitumor ability of tumor infiltrating CD8+ T cells and facilitated tumor immune escape in PDAC. Mechanistically, PLA2G2A regulated the function of CD8+ T cells as a pivotal soluble mediator via MAPK/Erk and NF-κB signaling pathways. In conclusion, our study identified the unrecognized role of PLA2G2A+ meCAFs in promoting tumor immune escape by impeding the antitumor immune function of CD8+ T cells, and strongly suggested PLA2G2A as a promising biomarker and therapeutic target for immunotherapy in PDAC.
What problem does this paper attempt to address?